Literature DB >> 23483282

Alternative treatment for bleeding peristomal varices: percutaneous parastomal embolization.

Waleska M Pabon-Ramos1, Matthew M Niemeyer, Narasimham L Dasika.   

Abstract

PURPOSE: To describe how peristomal varices can be successfully embolized via a percutaneous parastomal approach.
METHODS: The medical records of patients who underwent this procedure between December 1, 2000, and May 31, 2008, were retrospectively reviewed. Procedural details were recorded. Median fluoroscopy time and bleeding-free interval were calculated.
RESULTS: Seven patients underwent eight parastomal embolizations. The technical success rate was 88 % (one failure). All embolizations were performed with coils combined with a sclerosant, another embolizing agent, or both. Of the seven successful parastomal embolizations, there were three cases of recurrent bleeding; the median time to rebleeding was 45 days (range 26-313 days). The remaining four patients did not develop recurrent bleeding during the follow-up period; their median bleeding-free interval was 131 days (range 40-659 days).
CONCLUSION: This case review demonstrated that percutaneous parastomal embolization is a feasible technique to treat bleeding peristomal varices.

Entities:  

Mesh:

Year:  2013        PMID: 23483282     DOI: 10.1007/s00270-013-0588-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization.

Authors:  Yutaka Tomizawa; Atsushi Sakuraba; Joel Pekow
Journal:  ACG Case Rep J       Date:  2014-07-08

2.  Embolization of parastomal and small bowel ectopic varices utilizing a transhepatic antegrade approach: A case series.

Authors:  Ibrahim Mohammad Nadeem; Zain Badar; Victoria Giglio; Steffan Frosi Stella; George Markose; Sabarinath Nair
Journal:  Acta Radiol Open       Date:  2022-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.